Table 3.

Features of survey population, symptomatic pharmacists (group A), pharmacists with nonspecific symptoms (group B) and asymptomatic pharmacists (group C).

	Survey population n = 1632	Group A Symptomatic pharmacists n = 269	Group B Nonspecific Symptoms n = 355	Group C Asymptomatic Pharmacists n = 1008	Significance
Business Located in a Red Area, n (%)	576 (35,3%)	135 (50,2%)	127 (35,9%)	312 (31,0%)	Group A vs, B P < 0,0003
					Group A vs, C P < 0,00001
					Group B vs, C NS
Age, years	40,7 ($\pm$10)	39,6 ($\pm$8,9)	39 ($\pm$9,4)	41,5 ($\pm$10,4)	Group A vs, B NS
					Group A vs, C p = 0,038
					Group B vs, C p = 0,020
Gender, Women, n (%)	1289 (79%)	226 (84%)	294 (82,8%)	776 (77%)	Group A vs, B NS
					Group A vs, C p = 0,012
					Group B vs, C p < 0,00001
Presence of $\ge$1 Comorbidities, n (%)	269 (16,5%)	52 (19,3%)	82 (23,1%)	162 (16,1%)	Group A vs, B NS
					Group A vs, C NS
					Group B vs, C p = 0,003
Number of Pharmacy Owner, n (%)	359 (22%)	41 (15,2%)	61 (17,2%)	257 (25,5%)	Group A vs, B NS
					Group A vs, C p = 0,0004
					Group B vs, C p = 0,001
Number of Co-workers	4,2 (2,6)	4,4 ($\pm$2,7)	4,2 ($\pm$2,6)	4,2 (2$\pm$,6)	Group A vs, B NS
					Group A vs, C NS
					Group B vs, C NS
SARS-Cov-2 Tested Colleagues, n (%)	142 (8,7%)	41 (15,2%)	37 (10,4)	64 (6,3%)	Group A vs, B NS
					Group A vs, C p < 0,00001
					Group B vs, C p < 0,00001
SARS-Cov-2 Positive Co-Workers, n (%)	53 (3,2%)	23 (8,6%)	11 (3,1%)	19 (1,9%)	Group A vs, B p = 0,0029
					Group A vs, C p < 0,00001
					Group B vs, C NS
SARS-Cov-2 Positive Relatives, n (%)	33 (2,0%)	20 (7,4%)	5 (1,4%)	8 (0,8%)	Group A vs, B p = 0,0001
					Group A vs, C p < 0,00001
					Group B vs, C NS